Cytosorbents Corp

Current report

We are not in compliance with the requirements for continued listing on The Nasdaq Capital Market. Our common stock is subject to delisting, which would decrease the liquidity of our common stock and our ability to raise additional capital.

Current report

We are required to meet specified requirements to maintain our listing on The Nasdaq Capital Market, including a minimum bid price of $1.00 per share for our common stock and standards relative to minimum stockholders’ equity, minimum market value of publicly held shares and various additional requirements.

Current report

As previously disclosed, on October 2, 2025 we received notice from the Staff of Nasdaq that we were not in compliance with the Minimum Bid Price Requirement. We did not regain compliance during the initial 180-day period ended March 31, 2026, and on April 1, 2026 the Staff granted us a second 180-day compliance period, or until September 28, 2026, under Nasdaq Listing Rule 5810(c)(3)(A). Separately, on June 29, 2026 we received notice that our Market Value of Listed Securities was below the $35 million minimum required under Nasdaq Listing Rule 5550(b)(2), the MVLS Requirement, and under Nasdaq Listing Rule 5810(c)(3)(C) we have until December 28, 2026, to regain such compliance. As of the date of this report, we have not regained compliance with either requirement.

Current report

There can be no assurance that we will regain compliance with the Minimum Bid Price Requirement or the MVLS Requirement within the applicable compliance periods, or that we will otherwise satisfy the Nasdaq continued listing standards. We continue to actively monitor our performance with respect to the listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules. Actions we may take to regain compliance, such as effecting a reverse stock split, may not be successful or may not result in a sustained increase in our stock price or MVLS. If we do not regain compliance, Nasdaq will notify us that our securities are subject to delisting, at which point we may appeal to a Nasdaq Hearings Panel; a hearing request would generally stay any delisting action pending the Panel’s decision, but there is no assurance the Panel would grant continued listing. A delisting would likely reduce the liquidity and market price of our common stock, cause us to trade in the over-the-counter market, potentially subject our common stock to “penny stock” rules, impair our ability to raise capital, and reduce analyst coverage and institutional interest, any of which could have a material adverse effect on us.